News about "choriocapillaris"

Complement Therapeutics Receives US FDA Clearance to Begin Opti-GAIN Phase-I/II Trial of CTx001 in Patients with GA Secondary to AMD

Complement Therapeutics Receives US FDA Clearance to Begin Opti-GAIN Phase-I/II Trial of CTx001 in Patients with GA Secondary to AMD

CTx001, an AAV-based gene therapy, delivers a mini-CR1 protein to modulate complement pathways and address Geographic Atrophy (GA), an advanced dry AMD causing irreversible vision loss.

Choriocapillaris | 09/10/2025 | By Dineshwori


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members